Benzodiazepine receptor ligands: a patent review (2006 -- 2012) by Guerrini, Gabriella & Ciciani, Giovanna
1. Introduction
2. a-Subtype-selective ligands
3. GABAA receptor modulators
4. Labeled compounds
5. Patents of natural products
and derivatives
6. Expert opinion
Review
Benzodiazepine receptor ligands:
a patent review (2006 -- 2012)
Gabriella Guerrini† & Giovanna Ciciani
Dipartimento di Neuroscienze, Psicologia, Area del Farmaco e Salute del Bambino,
NEUROFARBA - “Sezione di Farmaceutica e Nutraceutica” Universita` degli Studi di,
Firenze, Italy
Introduction: Ligands at the benzodiazepine site of the GABAA receptor
(GABAA-R) act by modulating the effect of GABAA (g-aminobutyric acid).
The selective modulator effects of such ligands are related to the a-subunits
type (i.e., a1, a2, a3, and a5), being shown that the a1 subunit is associated
with sedative, anticonvulsant and amnesic effects; whereas the a2 and
a3 subunits mediate anxiolytic and myorelaxant effects. Recently it was
shown the involvement of a5 subunit in pain relief, which is involved in
cognitive processes of learning and memory.
Areas covered: This review covers patents, published from January 2006 to
October 2012, on ligands for the benzodiazepine binding site of the
GABAA-Rs. Patents filed from different companies and research groups report
many series of compounds that may be used in the treatment or prevention of
a large variety of neurodegenerative diseases.
Expert opinion: Most patents highlighted that various memory deficits,
related to Alzheimer’s disease, Down syndrome, mood disorders, schizophre-
nia, and age-related cognitive impairment may be treated using a5-selective
ligands. Other aspects related to the use of allosteric modulators of the
a7-nAchR and/or a5-GABAA-R (dual approach) for alleviating the impaired
cognition and the use of a2-selective ligands for pain relief are highlighted,
being particularly intriguing as new therapeutic approaches.
Keywords: benzodiazepine receptor ligands, cognitive impairment, GABAA subtype receptor
modulators, neurodegenerative diseases, neuropathic pain
Expert Opin. Ther. Patents [Early Online]
1. Introduction
The GABAA receptors (GABAA-Rs) are heteropentamer members of the Cys-
loop ligand-gated ion channel (LGIC) superfamily permeable to chlorine ions.
They are composed of two a-, two b-, and one g-subunits (despite the 19 total
subunits, i.e., a1 -- 6, b1 -- 3, g1 -- 3, d, ", t, p and r1 -- 3, that could arrange in
enormous number of theoretical pentameric combinations). Recently, Olsen and
Sieghart [1] reported the criteria to establish which GABAA subtype receptors are
unequivocally identified in the brain and a list of three categories of native receptor
subtypes was suggested, as “identified,” “existence with probability” and “tentative.”
Only 9 -- 11 different subtypes were identified in the brain up until now [1], but the
list is continuously being updated with new information. However the distribution
of the “identified” GABAA-Rs in the brain predicts that the combination a1bg2 is
the most abundant type (60%), being located in the cortex, hippocampal neurons,
thalamus, and cerebellum. The combination a2bg2 and a3bg2 are moderately
abundant (10 -- 20%) and they are found in the hippocampal formation, hypothal-
amus, and amygdale. Finally, the combination a5bg2 is expressed in the hippocam-
pus (pyramidal cells), amygdale, and hypothalamus (5%) [2]. The identity of the b
subunits in these combinations is lacking and often cannot be determined, because
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of the co-precipitation of all three subunits in immunoprecip-
itation or electrophysiological studies [3]. However, even if the
subunit b1 is the least common, the b2 is the most abundant
and widespread, whereas the b3 is more discrete. All b iso-
forms can exist in functional receptors, and usually as one
type per pentamer [3]. Subunits a4 and a3 are present in com-
bination with b2/3 isoforms and with the subunit d and rep-
resent a minor population of receptors in the striatum and
cerebellum [4].
The benzodiazepine site on GABAA-R (alternatively named
GABAA/Bz site, GABAA subtype receptor, or an-containing
GABAA-R basing on the contained a subunit) is one among
the numerous “binding sites” in the GABAA-R. In fact barbi-
turates, anesthetics, picrotoxin, neurosteroids, alcohol, and
Zn2+ can bind and directly activate or modulate the receptor
function [4]. In particular, benzodiazepine (Bz) and non-
benzodiazepine ligands bind the receptor in a site that lies at
the interface between the a/g subunit. These ligands act by
modulating the effect of GABA (g-aminobutyric acid), by
increasing the GABA-evoked chlorine current (agonist, positive
allosteric modulators [PAM]) or reducing (inverse agonist, neg-
ative allosteric modulators [NAM]) or not influencing the chlo-
rine flux (antagonist). The ability of Bz ligands to modulate
GABA-mediated channel activity depends on the presence of
the g-subunit in the pentamer, whereas their pharmacological
effects are related to the type of the a-subunits [5].
The proven clinical efficacy of the classical benzodiazepines
(anxiolytic, anticonvulsant, myorelaxant, and hypnotic) is
associated with several side effects such as sedation, memory
deficit, dependence, abuse liability and withdrawal syndrome
upon cessation of therapy [6]. Thus, the achievement of selec-
tive pharmacological effects is a challenge for researchers
active in this field and a variety of approaches have been
used to better understand the role of the different subunits
in the physiology and pathophysiology of CNS [5]. The
attempt to synthesize novel compounds to define the func-
tions of GABAA-R subtypes met with limited success. The
advent of the molecular genetics has delineated new perspec-
tives to define the relationships between the a isoform and
the pharmacological effects of the Bz site ligands [3]. The gen-
eration of transgenic mouse (knock-in mouse) with a point
mutation at the His residue, with Arg at the a1-3,5 subunits
(at position 101 in the a1- and a2-subunits, and in homolo-
gous residues in the a3- and a5-subunits, respectively) pro-
duced an-subtype receptors insensible to diazepam, and
permitted to identify the pharmacological activity of the spe-
cific mutate subunit [6]. In this way, it was shown that the
a1 subunit is associated with the sedative, anticonvulsant
and amnesic effects of diazepam. The a2- and a3-subunits
mediate the anxiolytic and myorelaxant effects of diazepam [7],
whereas the a5 subunit is involved in cognitive processes of
learning and memory [8]. These evidences support the hypoth-
esis that subtype-selectivity can lead to pharmacological selec-
tivity, allowing thus the obtaining of anxioselective drugs
devoid of sedative effects, as well as procognitive drugs without
anxiogenic or convulsant effects [8]. Further genetic studies have
been developed mainly with the aim to individuate new roles of
the a subunits and to find novel therapeutic opportunities. The
obtained results showed that the a2 subunits are involved in
schizophrenia [9,10], depression [11-13] and chronic neuropathic
pain [14-21]; the a5 subunits are involved in cognitive deficits
related to aging [22] and to the Down syndrome (DS) [23,24].
With the same aims, other strategies based on multi-targeted
therapy [25,26] and labeled drugs [27,28] have been used.
For the purpose of the present review, we have considered
World, US and EP Patents filed from Companies, Universi-
ties and individual authors between January 2006 and
October 2012, related to GABAA benzodiazepine receptor
ligands. The patents were selected from SciFinder data base
of Chemical Abstract (C.A.) and from Espacenet and have
been grouped according to a-subtype-selective ligands,
GABAA-R modulators, labeled and natural compounds. In
case where in vivo data were not given, the compounds were
chosen based on the in vitro data, selecting those compounds
that possess the highest affinity value (I%, IC50 or Ki). Other-
wise, a description of all pharmacological data (vitro and vivo)
was made by the authors of the review.
2. a-Subtype-selective ligands
2.1 Selective a5 GABAA inverse agonists
2.1.1 New compounds
Hoffmann-La Roche has filed numerous patent applications
in the field of a5-selective GABAA ligands. The compounds
reported in these patents are useful for neurological disorders
and in particular as cognitive enhancers or for therapeutic
and/or prophylactic treatment of cognitive disorders such as
AD. The affinity of these compounds at GABAA-R subtype
was measured by competition for [3H]flumazenil binding to
Article highlights.
. Most of the analyzed patents claim that GABAA
a5 inverse agonists or a5 agonists may be useful for
memory therapy associated with
neurodegenerative diseases.
. An intriguing aspect that was revealed regards the use
of a2/a3-selective ligands for the prevention or
suppression of neuropathic pain in addition to their
anxiolytic effects.
. The use of a dual approach (allosteric modulators of
a7-nAchR and/or a5-GABAA-R) is claimed as a
therapeutically relevant modality to ameliorate
CNS disorders.
. The chemical scaffolds of the claimed drugs show a
high degree of heterogeneity and an
enhanced flexibility.
. The label strategy is another topic reported in some
patents with the aim to obtain a higher metabolic
stability or useful diagnostics tools for imaging methods.
This box summarizes key points contained in the article.
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HEK293 cells expressing rat (stably transfected) or human
(transiently transfected) receptors of the composition a1b3g2,
a2b3g2, a3b3g2, a5b3g2 [29-55]. In most cases, the com-
pounds showed selectivity for the a5 subunit with respect to
a1, a2 and a3 subunits (Tables 1,2 and 3; binding data to
a1, a2 and a3 subunits are reported when available). This com-
pany claimed several chemical series related to imidazo[1,5-a]
[1,2,4]triazolo[4,3-d] [1,4]benzodiazepine (Table 1) [29-33],
isoxazole (Table 2) [34-53], and triazole derivatives (Table 3) [54,55].
2.1.2 Known compounds
Many companies/institutions reported in their application
known a5 inverse agonist ligands that, for the sake of clarity,
are grouped in Figure 1. The intellectual property is concerned
with the pharmacological, preclinic and clinical studies to
evaluate the cognitive impairment caused by various diseases
(psychiatric pathologies, DS, AS) or conditions (anesthesia,
inflammation, etc.).
The Governing Council of the University of Toronto
reports [56] methods for the prevention and or treatment of
memory impairment (long- and short-term) arising as a con-
sequence of excessive GABAA-Rs activation. This increased
activation can be caused by administration of an anesthetic
or by an increase in interleukine-1b (IL-1b) expression and/
or activity, induced by inflammation or surgery. This patent
is concerned with the protocols for planning the pharmaco-
logical studies and reports several references for each consid-
ered aspect. Data obtained from these studies disclosed the
therapeutic utility of the a5 inverse agonists. In particular,
L655708 [57] reverses memory deficit after exposure to the
anesthetic isoflurane and MRK-016 [58] reverses the memory
deficit associated with inflammation, both in young and
aging brain.
The invention of Cambridge Enterprise Ltd. [59]. reports to the
treatment of impaired cognitive function in patients with psychi-
atric conditions. In treated patients, the use of flumazenil [60]
improved cognitive performance, whereas healthy individuals
treated in the same way showed a slightly impaired performance.
The Centre National De la Recherche Scientifique (CNRS)
has deposited an application [61] in which the known com-
pounds L655708, MRK-016, RO4938581 [62], a5IA [8], hav-
ing inverse agonist functional selectivity for GABAA-Rs
containing a5 subunit, may possess superior efficacy to treat
cognitive impairment associated with DS. This was evaluated
by in vitro and in vivo tests on Ts65Dn mice, a murine model
of DS.
The Board of Trustees of the Leland Stanford Junior Uni-
versity [63] reported methods for improving cognitive functions
by administration of negative GABAA-R modulators a5IA,
RO4938581, RO4882224 [62], and GABAA-R antagonists, as
bilobalide, ginkgolide B and picrotoxine. The methods pro-
vided in this application consisted in the administration of
therapeutically effective doses of selected compounds so that
the peak concentration occurred when the subject was asleep.
Wisys Technology Foundation in the Patent US7595395 [64]
claimed pharmacological methods for the prevention and/or
Table 1. A list of the patents and representative compounds (Hoffmann-La Roche).
N
N
N
N
N
R1
R3
R2
Patent Compound* R1 R2 R3 Ki (nM)
a5 a1 a2 a3
US2006079507 [29] 33 Br H O 3.8 108.6 159.8 132.7
US2006084642 [30] 6 Br H CH2F 8.7 215.0 261.2 107.5
US2006128691 [31] 3 Cl H CH3 3.0 18.5 218.9 265.2
WO2006045429 [32] 3 OCH3 H Cl 0.8 12.2 17.2 11.7
WO2007042421 [33] 123 Br
N
O
H3C
CH3 0.6 188.1 - -
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
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Table 2. A list of the patents and representative compounds (Hoffmann-La Roche).
N O
R
R1X
R2
Patent Compounds* X R R1 R2 a5 Ki (nM)
WO2007074078 [34] 135 CH  
N
N
COCH3
H 1.64
WO2007082806 [35] 68 CH  N
N
H 5.5
WO2007074089 [36] 1 CH CH3
N
N
H 77.9
WO2007071598 [37] 127 CH CH3
N
N
O
F
OCH3
NHCH2CH2SCH3
H 1.7
US2007105922 [38] 21 CH CH3
O
OCH3
O H 1.4
US2007066668 [39] 162 CH CH3
NH
O
NH
OO
Cl 1.4
WO2007137954 [40] 50 CH CH3
N
N
CH3
COOC2H5
CH3
H 7.3
WO2009000662 [41] 40 CH CF3
N N
N
O
NH
F 4.1
WO2009071476 [42] 311 N CH3
NO
O
NH OH
Cl 0.1
US2009143385 [43] 102 N CH3
N
N
O
O
NHCH3
H 0.9
US2009143407 [44] 3 CH CH3
N
NO
O
NHCH
CH3
CH3
H 1.2
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zn-butyl is the substituent in 3-position of isoxazole.
G. Guerrini & G. Ciciani
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Table 2. A list of the patents and representative compounds (Hoffmann-La Roche) (continued).
N O
R
R1X
R2
Patent Compounds* X R R1 R2 a5 Ki (nM)
WO2010127968 [45] 8 CH CH3
N
N
O
O
NH O
H3C
H3C
H 6.9
WO2010112475 [46] 19 CH CH2OH NO
O
NHCH
CH3
CH3
Cl 0.4
WO2010127974 [47] 69 CH CH3
N
S
O
HN
O
CH3 H 0.3
WO2010127975 [48] 125 CH CH3
NN
O
H
N
CH3
O
F 0.4
WO2010127976 [49] 39 CH CH2OH
N
O
O
NH N O
F 0.8
WO2010127978 [50] 23 z CH3 NO
O
NH
N
N
CH3
^ 2.2
US2010256154 [51] 12 N CH3
N
N
O
O
NH N O
F 0.3
US2010216845 [52] 4 CH CH3
N
O
NH OH
H 2.0
US2010210651 [53] 16 N CH3
N
O
O
HN
O
O H 1.4
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zn-butyl is the substituent in 3-position of isoxazole.
Benzodiazepine receptor ligands: a patent review (2006 -- 2012)
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treatment of memory deficit. Among the drugs/compounds
used in this patent were the a-5 inverse agonists PWZ029 [65]
and XLi356 (Figure 2) [66]. From a full panel of receptor binding
was observed that XLi356 does not bind to other types of
receptors and, with PWZ029, were found to reverse
scopolamine-induced memory deficit (1 mg/kg) in mice at the
dose of 10mg/kg. XLi356 and PWZ029were not able to reverse
audio cued memory (amygdale-driven) suggesting that the
Table 3. A list of the patents and representative compounds (Hoffmann-La Roche).
N
N
N
R2
R3
R1
Patent Compounds* R1 R2 R3 a5 Ki (nM)
WO2012062687 [54] 37 N
F
CH3
NO
O
NH OH
CH3
H3C
1.7
WO2012076590 [55] 42 CH3
F N
N
N
O
NH
3.2
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
N
N
N
O
O
OCH2CH3
H3CO
H
N
N
N
N
O
N
NN
H3C
H3C CH3
CH3
NOH3C
N
N
N
CHF2
Br
N
N
N
N
NN
N O
O
N N
N
H3C
CH3
N
N
N
N
N
Cl
Cl
L655708 MRK-016
N
N
N
F
O
O
OCH2CH3
CH3
Flumazenil
WO2009016329 (Cambridge Enterprise Ltd.) [59]
WO2011024115 (Centre National de la Recherche Scientifique-CNRS) [62]
US20121574445 (The Board of Trustees of the Leland Stanford University) [63]
RO4938581 a5IA RO4882224
WO2012051707 (The Governing Council of The University of Toronto) [56]
WO2011024115 (Centre National de la Recherche Scientifique-CNRS) [62]
Figure 1. Structures of known a5 inverse agonists.
G. Guerrini & G. Ciciani
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effects of these compounds may be mediate through
a5 receptors located in the hippocampus (highly associated
with contextual memory).
This patent has been continuing-in-part of patent applica-
tion US20100130479 by James Cook [67] in which the com-
pound PWZ029, already studied for its cognitive enhancing
effect in rodents, was evaluated as cognitive enhancer in a
test of “executive function” in monkeys (Object Retrieval
with Detours [ORD]).
2.2 Selective a5 GABAA inverse agonists
and a7 nACh agonists
The Regents of the University of California, taking in account
the validity of the multi-targeted therapy, presented an inven-
tion [68] of dual compounds as a5 GABAA-Rs NAM and
a7 nAChRs PAM (Figure 3). Electrophysiological methods
were reported: several compounds were found to have maxi-
mum positive modulation at a7nAChRs greater than 500%
(till 1000%) at 10 µM. Other compounds showed maximum
negative modulation of a5 GABAA-Rs from 5 to 50% at
10 µM. Behavioral tests were performed to evaluate the effect
on memory: the compounds of the invention exhibited activ-
ity in the radial arm maze paradigm in a range between
0.1 and 10 mg/kg i.p. The tested compounds did not disrupt
rotarod performance, thus the possible CNS-depressant effect
being excluded.
2.3 Selective a5 GABAA agonists
Based on studies [69] that linked the age-related cognitive
decline and schizophrenia to a reduction of hippocampal
expression of a5 subunit of the GABAA-R, it has been sug-
gested the usefulness of a5-agonists in the treatment of
CNS disorders. Agenebio, Inc. filed two applications in this
field [70,71]. In these patents, the preferred compounds with
benzodiazepine or pyridazine scaffold (Figure 4) showed an
EC50 that induced greater than 5% potentiation of the
GABA-evoked chlorine current, showing a strong positive
allosteric modulatory effect on the a5 GABAA-Rs.
2.4 Selective a2/a3 GABAA agonists
A series of cinnoline and fused quinoline derivatives have been
claimed by Astrazeneca AB as GABAA-R modulators [72-75].
The inventions disclosed derivatives able to module the func-
tion and activity of GABA and GABAA-Rs in mammalian
subjects, to treat anxiety disorders, cognitive disorders associ-
ated with mood and schizophrenia. The therapeutic effect of
certain compounds as a2/a3 GABAA agonists, in the cogni-
tive impairment associated with schizophrenia, may be demon-
strated by using the EEG protocol. These compounds
attenuated the high-frequency EEG deficits present in schizo-
phrenic patients. In these international applications, [72-75],
GABAA-R binding assay was performed as reported in Table 4.
A patent application from the Zurich University [76]
reported to the use of a2/a3 GABAA agonists or partial ago-
nists for the treatment of neuropathic pain. In vivo tests to
assess the sensitivity to tonic nociceptive stimulation (formalin
test) and the pro- or antinociceptive effect in the chronic con-
striction injury (CCI) model were reported for selected known
N
N
N
Cl
O
CH2OCH3
CH3
N
N
N
H3CH2C
O
CH3
O
O
(CH2)3
N
N
N
CH2CH3
OH3C
O
O
PWZ-029  Ki (nM) α5 = 38.8; α1/α2/α3 = 300 XLi356  Ki (nM) α5 = 107; α1/α2 > 2000; α3 = NT
US7595395 (Wisys Technology Foundation) [64]US7595395 (Wisys Technology Foundation) [64]
US20100130479 (Cook) [67]
Figure 2. Examples of known a5 inverse agonists claimed by Wisys Technology Foundation and James Cook.
N
N
N
NN
H
F
F
Example 1  NAM a5 GABAA-R; PAM a7 AchR
WO20100104843 (The Regents of the University of California) [68]
Figure 3. Example of compound claimed by The Regents of
the University of California.
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NN
N
N
N
CH3
CONEt2
H3CO
N
N
R
R1
Compound 7 
WO2012068149 [70]
GABA α5 EC50 % potentiation = 11.1
Compound 27
WO2012068161 [71]
GABA α5 EC50 % potentiation = 30.5
Compound 4
WO2012068161 [71]
GABA α5 EC50 % potentiation = 42
N
N
Cl
NO
COOCH3
Figure 4. Examples of compounds claimed by Agenebio, Inc.
Table 4. A list of the patents and representative compounds (Astrazeneca AB).
N
N
NH2
R2
R1
O
N
H
R3
Patent Compounds* R1 R2 R3 Ki (nM)
WO2007073283 [72] 64 H
FH3CO
(CH2)2CH3 a2 = 0.144
WO2008155573 [73] -z H
FH3CO
CH2CH3 a2 = 0.301
WO2011021979 [74] I F
N
N
H3CO
OCH3
a1 = 0.11 ± 0.03
a2 = 0.65 ± 0.45
a3 = 0.99 ± 0.16
a5 = 35.3 ± 8.5
WO2008155572 [75] -z
N
N
ONH2
N
OCH3H3CO
F
a2 = 0.774
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zNumber not reported.
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compounds, L838417, TPA023, CL218872, SL651498,
Ocinaplon (10 mg/kg p.o.) versus diazepam (0.09 mg/kg i.t.
or 10 mg/kg p.o.) (Figure 5). For some of these compounds,
detailed information is available in the references cited in the
same patent and in the recent literature [21].
James Cook and Wisys Technology Foundation have pat-
ented [77,78] a series of compounds with benzodiazepine scaf-
fold fused with a heterocyclic five-membered ring (Table 5),
with selective agonist efficacy at GABAA a2/a3 in compari-
son with a1, despite the high affinity to all subtype receptors.
N
N
O
CH3
F
O
N
N
N N
O
N
N
SL651498 Ocinaplon
WO2006061428 (Universitat Zurich) [76]
N
N
NN
O
N
N
N
CH3
F
F
H3C
H3C CH3
N
N
NN
O
N
N
N
C2H5
F
H3C
H3C CH3
N
N
N
N
CH3
CF3
L838417 CL218872TPA023
Figure 5. Examples of compounds claimed by Universitat Zurich.
Table 5. A list of the patents and representative compounds (Cook and Wisys).
N
N
N
C
HC
X
COOCH2CH3
R
Patent Compounds R X Ki (nM)
a1 a2 a3 a5
US2010317619 [77] XHe-II-53 H CH 287 45 96 138
JY-XHe-053 H CF 21.99 12.34 34.9 0.671
HZ166 H N 118 148 365 76.88
US7618958 [78] SH-053-s-CH3 CH3 CH Anxiolytic activity without suppressing locomotor
activity 56 -- 100 mg/kg
Benzodiazepine receptor ligands: a patent review (2006 -- 2012)
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Cook and co-workers reported in a US application [77] meth-
ods for suppression, alleviation and prevention of the neuro-
pathic and inflammatory pain. Preferred compounds (XHe-
II-53, JY-XHe-053, and HZ166) were tested (8 -- 150 mg/kg)
for the ability to suppress the pain (thermal hyperalgesia and
mechanical sensitivity) in the chronic constriction injury (CCI)
and the inflammatory pain with the formalin test models. The
ability of these compounds to suppress pain with minimal ataxic
and sedative effects is reflecting their selectivity for a2 or
a3 compared to a1.
For the treatment of anxiety, Wisys Technology Founda-
tion has patented [78] a series of compounds tested in a rodent
model of anxiety and locomotor activity. The compound
SH-053-s-CH3 showed anxiolytic activity without suppress-
ing locomotors activity from 56 until to 100 mg/kg.
2.5 Selective a1 GABAA agonists
A series of patents claiming several bicyclic heteroaromatic
compounds with pyrazolopyrimidine, imidazopyrimidine,
imidazopyridine, imidazopyridazine and quinolone scaffolds
were registered by Ferrer Internacional S.A. [79-87]. The inven-
tions describe novel classes of subtype-selective a1 relative to
a2 GABAA-R ligands, useful in the treatment and prevention
of sleep disorders, insomnia and epilepsy.Many of the novel com-
pounds with pyrazolopyrimidine scaffold (Table 6) [79-82] and the
quinolone derivatives (Figure 6) [83] were evaluated in vitro and
in vivo. Good a1 affinity values were evidenced and the in vivo
effects were assessed by predictive sedation-hypnosis tests in
Table 6. A list of the patents and representative compounds (Ferrer Internacional SA).
N
N N
R3
R7
Patent Compounds* R3 R7 Ki (nM)
a1 a2
EP1648896 [79] 15 NO2 N
CH2CH3
SO2CH3
11.1 295.8
EP1648897 [80] 19
S
O
N
CH2C
S CH2CH2CH3
OO
CH
0.5 4520
EP1899343 [81] 2
S
O
N
CH3
C
CH3
O
F
2.1 20
WO2008015253 [82] 5 NO2
N
CH3
S CH3
OO
F
-z -
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zOnly specific binding, expressed as % inhibition, is reported (98.2% at 10-5 M). No IC50 or Ki values are reported.
N
O
H3C
O
N
N
H
Compound 15  α1 affinity I% = 87.3
US20100168099 (Ferrer Internacional SA) [83]
Figure 6. Examples of known compounds claimed by Ferrer
Internacional SA.
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mice (expressed as percentage of crossings of treated animals ver-
sus controls, 89 -- 95%) with respect to the reference compound
zaleplon (84.9%).
As concerning the imidazole derivatives (Figure 7) in which
the heterocyclic ring is variously fused with pyridine, pyrimi-
dine and pyridazine moieties, the in vitro and in vivo tests
were reported in four patents [84-87]. Certain compounds
exhibited high selectivity for the a1 GABAA subtype receptors
with respect to the a2 ones, suggesting their possible use in
diseases or conditions in which preferential activity on the
a1 receptors is desirable, such as insomnia, anesthesia, induc-
tion of sleep and sedation. Affinity data were expressed as per-
centage inhibition (I%) at 10-5 for a1 and for a2 subunits
and the percentage inhibition of motor activity was in the
85 -- 92% range.
3. GABAA receptor modulators
Many companies and institutions reported in several patents
on ligands binding to the GABAA/Bz site that could be used
in the treatment and/or prevention of a variety of disorders
of the central nervous system in particular in anxiety and
related diseases. In vitro inhibition of 3H-flunitrazepam
(3H-FNM) binding was performed and the affinity value of
the tested substance, which inhibits the specific binding of 3H-
FNM by 50%, was given as IC50 or Ki values. All reported com-
pounds may be also useful in their labeled form as radiotracers
for positron emission tomography (PET) imaging or for single
photon emission computerized tomography (SPECT).
Neurosearch has filed a series of 17 [88-104] patents concern-
ing novel benzimidazole derivatives (Table 7) and
4 patents [105-108] describing imidazole derivatives (Table 8),
active from the submicromolar to the picomolar range (IC50
0.10 -- 0.00029 µM).
Neurogen published 11 patents and/or applications [109-119] in
which are reported numerous heterocyclic compounds (around
2400 derivatives) exhibiting Ki values in the range of
1 µM -- 10 nM.To rationalize all these compounds we have sum-
marized themost representative chemical scaffolds and structures
in Figures 8, 9 [109,116-119], in Table 9 [110,113-115,120], Table 10 [111]
and Table 11 [112]. In Table 9, for the sake of simplicity, we also
report the structures described by Yuelian, in the patent
N
N
N
H3C CH3
H3C
O
N CH3H3C
N
N
H3C CH3
O
N
CH3H2N
N
N
N
CN
N
CH2CH3
SO2CH3
N
N
N
H3C CH3
O
N
C4H9
C4H9
Ex 22
α1 affinity: I% 84.8 10-5 M
α2 affinity: I% 9.4 10-5 M
Ex 6
α1 affinity: I% 99.0 10-5 M
α2 affinity: I% 71.6 10-5 M
Ex 5
α1 affinity: I% 97.6 10-5 M
α2 affinity: I% 48 10-5 M
WO20060084835 [86] WO2007110437 [87]
Ex 6
α1 affinity: I% 100 10-5 M
α2 affinity: I% 86.6 10-5 M
Figure 7. Examples of compounds claimed by Ferrer Internacional SA.
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Table 7. A list of the patents and representative compounds (Neurosearch).
N
N
X
Y
R7
R5
R1
Patent Compounds* X Y R1 R5 R7 IC50 (mM) I%
‡
WO2006111517 [88] 23 CH CH
N
N
O
CH3
CH3 H 0.0026
WO2006111516 [89] 22a CH CH
N N
N
CH3O CH3
N OH
H 0.0021
WO2006108800 [90] -§ CH CH
N
S
O H
NH H 0.0048
US2006148856 [91] -§ CH CH
N
N H 75%
WO2007065864 [92] 12g CH CH
H3CO CH3
NH
O
CH3
H 0.0026
WO2007110374 [93] 9aac CH CH
H3CO
O
NH2
H 0.00065
US2007021482 [94] 6 CH CH H H
N OH NH2
0.0042
WO2010055124 [95] 8a CH CH
N
CN CH3
NH2
H 0.0085
WO2010055125 [96] 8f CH C-F
N
N
OCH3
OCH3
CH3
NH2
H 0.0026
WO2010055126 [97] 8a N CH CN CH3
NH2
H 0.0049
WO2010055127 [98] 8a1 CH N Cl CH3
NH2
H 0.019
WO2010055128 [99] 7d CH C-F
N
OCH3 CH3
OH
CH3
H 0.00029
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zSpecific binding (I%) must be obtained, before calculation of IC50.
§Number not reported.
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application [120] because of the similarity of the nucleus. Preferred
compounds of this inventions exhibited Ki < 100 nM and the
most preferred ones hadKi values < 10 nM. InTable 11we report
three compounds and the most representative general structures
chosen among the numerous derivatives reported in the consid-
ered patent [112].
Helicon filed patent applications on pyrazoloquino-
lines [121,122], pyrazolonaphthyridines [123], and dipyrazolopyr-
idines [124]. General binding data are reported and expressed
as percentage of inhibition (I%) (Table 12).
A series of quinolone derivatives fused with isothiazole and/
or isoxazole rings were registered by Forskarpatent I Syd
AB [125] together with their binding mode in a pharmaco-
phoric model. The affinity for GABAA/Bz (rat cortical mem-
branes) was also measured. The Ki range of these novel
compounds was of 1.9 -- 18 nM and the company claimed a
method for treating anxiolytic, anticonvulsant, sedative-
hypnotic, and myorelaxant conditions in mammalians,
including humans (Figure 10).
4. Labeled compounds
Concert Pharmaceutical, Inc. patented the deuterated form of
several known compounds, since they show a higher meta-
bolic stability but a comparable pharmacological activity
with respect to non-deuterated analogs. The determination
of metabolic stability was performed in vitro, evaluating the
“percentage parent remaining” (% PR) that refers to the per-
centage of starting material remaining at a specified time
point (i.e., 30 min). Concert Pharm., in the field of GABAA
ligands seems to be a newcomer and filed five patents [126-130]
in which reported several deuterated analogs in the “various
possible position” of the considered structures. The deuter-
ated analogs of TPA023 (a1 antagonist; a2/a3 partial
Table 7. A list of the patents and representative compounds (Neurosearch) (continued).
N
N
X
Y
R7
R5
R1
Patent Compounds* X Y R1 R5 R7 IC50 (mM) I%
‡
WO2010055129 [100] 7a CH C-F OCH3
F
CH3
OH
CH3
H 0.00049
WO2010055130 [101] 7a N CH
N
F CH3
OH
CH3
H 0.0023
WO2010055131 [102] 7g N CH Cl
CN
CH3
OH
CH3
H 0.0013
WO2010055132 [103] 7a CH N
N
OCH3 CH3
OH
CH3
H 0.0012
WO2010055133 [104] 7b CH N CN
Cl
H H 0.016
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zSpecific binding (I%) must be obtained, before calculation of IC50.
§Number not reported.
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agonist), NS11394 (a3 agonist), a5IA (a5 inverse agonist)
L838417 (a1 antagonist; a2/a3/a5 agonist), and pagoclone
(a3 full agonist; a1/a2/and a5 partial agonist) are shown
in Figure 11.
An important aspect developed by GE Healthcare Ltd is
related to compounds useful for in vitro diagnostics and
in vivo imaging of the GABAA-Rs. In particular, these inven-
tions [131,132] deal with quinoline and carboline derivatives
showing Ki value £ 20 nM at the GABAA/Bz site from rat
cerebellar membranes. It was claimed that these novel
compounds may be prepared with a detectable label,
for example, 18F for PET or SPECT imaging methods.
In Figure 12 are reported the only two labeled synthesized
compounds claimed in this patent.
5. Patents of natural products and derivatives
Wien University has filed a patent application [133] for piper-
ine derivatives as new anxiolytics with significantly reduced
sedative properties without affect transient receptor potential
vanilloid 1 (TRPV1). SCT-64 (ex 35) and SCT-66 (ex 36)
(Figure 13) show dose-dependent anxiolytic activity at
0.3 -- 10 mg/kg in elevated plus maze (EPM) test.
6. Expert opinion
This review presents an overview of the most interesting
GABAA-R modulators patented starting with 2006 till the
present period, and can be considered an update of the previ-
ously published reviews [134,135].
The Bz-binding site on GABAA-R has historically received
much attention and since 1980 century many efforts were
made to develop a pharmacophore/receptor model for ago-
nists, antagonists and inverse agonists, by using a variety of
Table 8. A list of the patents and representative compounds (Neurosearch).
N
N
R1
R2
Patent Compounds* R1 R2 IC50 (mM)
‡
WO2007042543 [105] -§ CN 0.10
WO2007042544 [106] -§ ON
N
H3C
OCF3 0.017
WO2007042545 [107] 11a -COOC2H5
N
O
0.024
WO20070472546 [108] 14
N
O OCH3
F
0.0027
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zSpecific binding (I%) must be obtained, before calculation of IC50.
§Number not reported.
N
NN
N
N
X
R
R1
WO2006093911 [109]  (Neurogen)
R = alkyl; R1 = CN, F; X = S, O
Ki < 1 μM
Figure 8. Example of compound claimed by Neurogen.
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OArN
A
O
Ar
N
R
R1
US20061353367 [116]
Ar = Ph, Py
R = alkyl
R1 = heteroaryl methyl
US2006160842 [117]
Ar = Ph, Tiofene, Furane
R = alkyl
R1 = heteroaryl methyl
US2008032975 [119]
Ar = tetrahydroindazole, indole
R = H
R1 = monociclyc aryl/heteroaryl system
US2008146546 [118]
Ar = heteroaromatic bicyclic system
A = piperidine, pirrolidine, morfoline
Figure 9. Other compounds claimed by Neurogen.
Table 9. A list of the patents and representative compounds (Neurogen and Xu Yuelian).
N
R1
NN
R
R2
Patent Compounds* R R1 R2
WO2006078891
Neurogen [110]
63 N N
N
N
Pr
H3C F H
73 N N
N
N
Pr
H3C F H
79 N N
Pr
N
N
H3C F H
90 N
PrNH3C
F H
96 N
Pr
N
N
F H
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
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Table 9. A list of the patents and representative compounds (Neurogen and Xu Yuelian) (continued).
N
R1
NN
R
R2
Patent Compounds* R R1 R2
102 N
Pr
S
NH3C
F H
US2006247245
Xu Yuelian [120]
Ex 5
N
N
N
Pr
H3C F H
Ex 7
N
N
N
N
Pr
CH3
H H
Ex 9
N
N
N
N
Pr
H3C
F H
EP1880998
Neurogen [113]
106
N
N
Pr
N
H F
130
N
N
Pr
N
NH3C
F H
186
N
N
PrN N
H3C
F H
US7271170
Neurogen [114]
213
N
N
PrN
CH3
H F
US20090023737
Neurogen [115]
111
N N
Pr
N
H F
126
N N
Pr
N
H3C
H F
128
N N
CH2CH3
N
N
H F
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
G. Guerrini & G. Ciciani
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Table 10. A list of the patents and representative compounds (Neurogen).
N
R1
N
NR
Patent Compounds* R R1
WO2006052546 [111] 106
N
N
Pr
F
125
N
N
N
N
Pr
H3C
F
215
N
N
N
Pr
F
217 N
N
N
Pr
CH3
F
307
N
N
Pr
F
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
Table 11. A list of the patents and representative compounds (Neurogen).
R1
NN
R
Patent Compounds* R R1
US20060014746 [112] Ex 9
N
N
CF3
N
F
Ex 11
N N
N
CH2CH3O
H3C S
N
Ex 13
N
S
N
CH2CH3
N
F
General structures in US20060014746 [112]
NN
N Aryl/Heteroaryl
(further substituted)
NN
N
NN
N
NN
N
NN
N
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
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techniques (e.g., chemical synthesis, radioligand binding,
and receptor mapping) affording thus Cook’s model [136].
The determination of the crystal structure of water-soluble
acetylcholine binding protein (AChBP) [137] has generated
much interest also for the study of the GABAA-R, and several
comparative modeling studies have been proposed for the last
one [138,139]. At the same time the discovery of molecular
genetics and pharmacological approaches permitted to
elucidate the relationship between the a-subunit and
the pharmacological effect of classical benzodiazepines, and
to develop selective anxiolytic, anticonvulsant, myorelaxant,
sedative and promnemonic drugs. At the present it is
particularly intriguing the use of the a-subtype selective
ligands as synergic compounds in multi-targeted therapy for
CNS diseases.
It is interesting to highlight that the majority of the patents,
in the period 2006 -- 2012, have been filed by companies
(e.g., Hoffmann La-Roche, Neurogen Corp., Neurosearch A/
S, and Wisys Technology Foundation, Inc.), extensively
engaged in this research field. The a-subtype-selective ligands,
developed by these companies, are claimed in the reviewed pat-
ent applications, and represent around 70% of the considered
patents. Companies such as Ferrer Internacional S.A., Helicon
Therapeutics, Inc., Agenebio, Inc., Astrazeneca AB, Concert
Pharmaceutical, Inc., GE Healthcare Ltd, and some University,
represent the remaining 30%, and are newcomers in this field.
The structural heterogeneity of the compounds reported in
the reviewed patents does not permit to individuate a pharma-
cophore moiety for subtype-selective ligands. The novel com-
pounds claimed in these patents are mainly represented by
heterocycles (mono- or bicyclic, eventually further substituted
with other ring systems), while the previously described
Table 12. A list of the patents and representative compounds (Helicon).
N
A
NN
O
R3
Patent Compounds* A R3 IC50 (nM) or I%
‡
WO2008154442 [121] 45 F3C
N N
CH3
CH3
O < 1.0
WO2008154438 [122] 19a
F
N
O H < 1.0
WO2008154447 [123] 6c
NN
O H < 1.0
WO2012051213 [124] 6b
N
N
O NHCH2CH3
H > 80%
*Original number compound used in the cited patents: selection, made by the authors, of the most representative structures.
zSpecific binding must be obtained, before calculation of IC50.
I%: Percentage of inhibition at 0.1 µM.
N
H
O
X
N
R2
R1
WO2009123536 [125] (Forskapatent I Syd AB)
X  = S, O
R1 = H, CH3, OCH3, NO2, Br, C2H5, C3H7,
R2 = PhCH3, PhBr, NHCOCH3
Ki  range 1.9 − 18 nM
Figure 10. Examples of compounds claimed by Forskapatent
I Syd AB.
G. Guerrini & G. Ciciani
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benzodiazepine receptor ligands showed a planar nitrogen
polycyclic scaffold. Thus, a major conformational flexibility
in the structure seems to be tolerated for binding on
GABAA-R. For example Hoffmann La Roche “simplified”
the rigid tetracyclic scaffold (imidazotriazolobenzodiazepine
reported in the 2006 and 2007 patent applications), which
led to isoxazole and triazole derivatives.
In addition to several patent applications claiming com-
pounds acting as no-selective GABAA-R modulators, most of
the reviewed patents highlighted that different types of memory
deficits related to AD, DS, mood disorders, schizophrenia and
age-related cognitive decline, may be treated using a5-inverse
agonists and/or a5-agonists. Moreover, taking into account
that many neurotransmitters are involved in neurodegenerative
N
N
N
N
F
O
CD3D3C
D3C
N
N
N
CD3
N
N
NC
CD3HO
D3C
N
N
NN
O
N
N N
O
N
CD3
D
D
D
CD3
N
N
NN
O
N
N
N
F
F
D3C
D3C CD3
CH3
N
N
N
Cl
O
CD3
D3C
O
D D
D
Compound 109 (analogue of TPA023)
WO2011005520 [126]
Compound 115 (analogue of α5IA)
WO2011020044 [128]
Compound 103 (analogue of L838417)
WO2010025407 [129]
Compound 121 (analogue of pagoclone)
WO2012116288 [130]
Compound 102 (analogue of NS11394)
WO2011047315 [127]
Figure 11. Example of known compounds claimed from Concert Pharmaceutical.
N
H
N
O
NH 18F
N
H
O O
NH
18F
4  [18F]
WO2008132454 [131]
6b  [18F]
WO2009040377 [132]
Figure 12. Examples of compounds claimed from GE Healthcare Ltd.
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diseases, the use of a dual approach (allosteric modulators of
a7-nAchR and/or a5-GABAA-Rs) as claimed fromThe Regents
of the University of California, might be a therapeutically rele-
vant modality to ameliorate CNS disorders. The enhancer cogni-
tion topic covers a wide part of the research by the drug
companies, as shown by the high number of filed patents.
Another attractive aspect that stands out in this review is
the use of a2/a3-selective ligands for the prevention or
suppression of neuropathic pain in addition to anxiolytic
effects, which represents an intriguing approach, whose research
is still in progress.
It is important to point out that the label strategy is another
topic reported in several patents, either for improving phar-
macokinetic properties without impairing pharmacodynamics
properties or for generating diagnostic tools.
All these data show that since 2000 the study and development
of subtype-selective receptor ligands is in progress with the aid of
classic or more modern approaches. The promising aspect that
arises is referred to the possibility to treat particular deficits that
are not directly related to GABAergic neurotransmission.
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